BJDX CEO Indranil purchased 12,500 shares at $2.00 in non-discretionary private placement; stock now trades at $1.72, down 89.7% from 52-week high.
Dey Indranil (President and CEO) purchased 12,500 shares of Bluejay Diagnostics at $2.00 on 2026-03-14, raising his holdings from 22 shares to 12,522 shares. However, this transaction is a private placement—not a discretionary open-market purchase—and therefore cannot be interpreted as a buying signal driven by insider conviction. The stock has declined sharply: the current price of $1.72 is 89.7% below the 52-week high of $16.68, and the company remains unprofitable with a net income of $-1.9M against revenue of $249.0K. Given the structured nature of the placement and the company's weak financial position, investors should focus on the underlying business fundamentals rather than attributing strategic meaning to the timing or sizing of this purchase.